Mike Kratky
Stock Analyst at Leerink Partners
(2.79)
# 1,893
Out of 5,090 analysts
35
Total ratings
50%
Success rate
32.93%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Outperform | $127 → $128 | $97.52 | +31.26% | 2 | Oct 1, 2025 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $116 → $97 | $136.81 | -29.10% | 7 | Aug 15, 2025 | |
| MDT Medtronic | Initiates: Outperform | $110 | $101.36 | +8.52% | 1 | Jun 16, 2025 | |
| BBNX Beta Bionics | Initiates: Outperform | $28 | $29.38 | -4.70% | 1 | Feb 24, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | $25 → $12 | $17.77 | -32.47% | 2 | Feb 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $65.49 | +32.84% | 2 | Oct 25, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $300.66 | -12.53% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $20.92 | +115.11% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $16.40 | +34.15% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $304.49 | -39.57% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $36.23 | +15.93% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $342 | $575.34 | -40.56% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $86.19 | -12.98% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $35.86 | +3.18% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $33.32 | -72.99% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $27.46 | +82.08% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.21 | +3,619.01% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $577.30 | -45.44% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $66.62 | -53.47% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $22.84 | -38.70% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $32.02 | +24.92% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $392 → $384 | $34.47 | +1,014.17% | 1 | Aug 11, 2022 |
Boston Scientific
Oct 1, 2025
Maintains: Outperform
Price Target: $127 → $128
Current: $97.52
Upside: +31.26%
Inspire Medical Systems
Aug 15, 2025
Maintains: Market Perform
Price Target: $116 → $97
Current: $136.81
Upside: -29.10%
Medtronic
Jun 16, 2025
Initiates: Outperform
Price Target: $110
Current: $101.36
Upside: +8.52%
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $29.38
Upside: -4.70%
10x Genomics
Feb 13, 2025
Downgrades: Market Perform
Price Target: $25 → $12
Current: $17.77
Upside: -32.47%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $65.49
Upside: +32.84%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $300.66
Upside: -12.53%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $20.92
Upside: +115.11%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $16.40
Upside: +34.15%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $304.49
Upside: -39.57%
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $36.23
Upside: +15.93%
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $575.34
Upside: -40.56%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $86.19
Upside: -12.98%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $35.86
Upside: +3.18%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $33.32
Upside: -72.99%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $27.46
Upside: +82.08%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.21
Upside: +3,619.01%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $577.30
Upside: -45.44%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $66.62
Upside: -53.47%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $22.84
Upside: -38.70%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $32.02
Upside: +24.92%
Aug 11, 2022
Maintains: Outperform
Price Target: $392 → $384
Current: $34.47
Upside: +1,014.17%